Top Story
FDA opens investigation into Novartis' Zolgensma after cancer cases reported
The U.S. Food and Drug Administration announced on Friday that it is opening a formal investigation into the gene-therapy product Zolgensma, marketed by Novartis for spinal muscular atrophy. The agency said it has identified a serious risk of cancer that appears to be linked to the treatment, prompting the probe. Novartis disclosed the occurrence of cancer cases in patients who received Zolgensma the day before the…
Endpoints↗ source
RegulatoryNegative